Pharmafile Logo

News and Press Releases

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

22 September 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 22, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 million Potential sales milestones of $180 million or more in first 10 years of commercialization Royalties equaling 25% of...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 15, 2025

Ocugen
11 Great Valley Parkway Malvern, PA 19355

PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025

4 September 2025 -- Paris, France -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will...

Category: Clinical Trials, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: September 4, 2025

Fidia Farmaceutici enters the UK market with the acquisition of Altacor Ltd

Marking another significant milestone in its ongoing international expansion, the Company enters the rapidly-growing UK ophthalmology market, a key therapeutic area for the Group 3 September 2025 -- Abano Terme,...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: September 3, 2025

Fidia Farmaceutici
Via Ponte della Fabbrica 3/A – 35031 Abano Terme (PD) – Italy

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025

Resolution Therapeutics
contact@resolution-tx.com
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU

Oxeltis and academic partners receive grant funding worth nearly €800,000 to develop antiviral for Bunyaviricetes 

France’s National Research Agency (ANR) and Defense Innovation Agency (AID) will finance BUNYANTIVIR project to introduce novel therapeutic approach for Bunyaviricetes class of human pathogenic viruses found in tropical and...

Category:
Posted: June 25, 2025

Oxeltis
Cap Gamma, 1682 rue de la Valsière, BP 7247 34086 Montpellier Cedex 4 – France

Celltrion opens new UK headquarters in Uxbridge, UK

New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...

Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025

Celltrion
23, Academy-ro, Yeonsu-gu, Incheon, Republic of Korea

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025

OptymEdge
11414 West Park Place, Suite 202, Milwaukee, WI 53224, US

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

Advarra Integrates Study Startup and IRB Technologies, Enabling Unprecedented Visibility into Clinical Trial Site Activation

New release of Advarra’s Study Collaboration solution provides sponsors and CROs a single view into the progress of site activation milestones and IRB review status across sites 17 April 2025...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

Advarra
6100 Merriweather Dr., Suite 600 Columbia, MD 21044

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

Pistoia Alliance Launches Initiative to Assess Sustainability of Digital vs. Traditional Clinical Trial Approaches

New initiative will collect pharma and CRO data to refine industry carbon measurement of technologies like remote monitoring and eConsent, informing more sustainable trial design 20 March 2025, Massachusetts, US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

The Pistoia Alliance
info@pistoiaalliance.org
401 Edgewater Pl, Wakefield, Massachusetts, US

Innovaderm Research Rebrands as Indero, a dual-focus CRO 

7 March 2025 -- Quebec, Canada -- Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 7, 2025

Indero
3530 Saint-Laurent boulevard, Suite 300 Montreal, QC, H2X 2V1, Canada

Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery From Plasmid to Structure

Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure 28 January 2025 – Baltimore, MD, US – Sapio Sciences, the science-aware™ lab informatics platform,...

Category: BioManufacturing, Drug Discovery
Posted: January 28, 2025

Sapio Sciences
400 East Pratt Street #800 Baltimore, MD 21202